KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Common Equity (2016 - 2025)

Moderna (MRNA) has disclosed Common Equity for 9 consecutive years, with $8.6 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 20.65% to $8.6 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $8.6 billion, a 20.65% decrease, with the full-year FY2025 number at $8.6 billion, down 20.65% from a year prior.
  • Common Equity was $8.6 billion for Q4 2025 at Moderna, down from $9.3 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $19.1 billion in Q4 2022 to a low of -$10.0 million in Q1 2025.
  • A 5-year average of $12.2 billion and a median of $12.4 billion in 2024 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 452.32% in 2021, then crashed 100.08% in 2025.
  • Moderna's Common Equity stood at $14.1 billion in 2021, then surged by 35.19% to $19.1 billion in 2022, then dropped by 27.55% to $13.9 billion in 2023, then fell by 21.32% to $10.9 billion in 2024, then decreased by 20.65% to $8.6 billion in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Common Equity are $8.6 billion (Q4 2025), $9.3 billion (Q3 2025), and $9.4 billion (Q2 2025).